

CIN-L72200TG1997PLC028374

Date: 29.03.2024

To,

Department of Corporate Services	National Stock Exchange of India Ltd
Bombay Stock Exchange Limited	Exchange Plaza
Floor 25, PJ Towers	Bandra Kurla Complex
Dalal Street,	Bandra (E),
Mumbai – 400 001	Mumbai 400 051

Dear Sir,

Sub: Outcome of the Board Meeting held on 29.03.2024

Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, this is to inform you that the Board of Directors in their just concluded Board meeting held today have:

- 1. Considered and adopted the standalone and consolidated audited financial results of the Company for the quarter / year ended 31.03.2023;
- 2. Considered and adopted the standalone and consolidated un-audited financial results of the Company for the quarter / three months ended 30.06.2023;
- 3. Considered and adopted the standalone and consolidated un-audited financial results of the Company for the quarter / half year ended 30.09.2023;
- 4. Considered and adopted the standalone and consolidated un-audited financial results of the Company for the quarter / nine months ended 31.12.2023;

In this connection find attached the following:

- 1. Copy of standalone and consolidated audited financial results of the Company for the quarter / year ended 31.03.2023 alongwith Audit Report & declaration of unmodified opinion.
- 2. Copy of standalone and consolidated un-audited financial results of the Company for the quarter / three months ended 30.06.2023 alongwith Limited Review Report
- 3. Copy of standalone and consolidated un-audited financial results of the Company for the quarter / half year ended 30.09.2023 alongwith Limited Review Report
- 4. Copy of standalone and consolidated un-audited financial results of the Company for the quarter / nine months ended 31.12.2023 alongwith Limited Review Report

The meeting commenced at 3.30 PM and ended at 6.45 PM.

This is for your information and records.

Thanking you Yours truly

For Celestial Biolabs Limited

AMIT KUMAR SINGH Digitally signed by AMIT KUMAR SINGH Date: 2024.03.29 18:46:14 +05'30'

Amit Kumar Singh Managing Director DIN: 01824426



LIMITED REVIEW REPORT

To, The Board Members of Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for quarter ended 31 December ,2023", and year to date results for the period from 01 April 2023 to 31 December 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Financial Results , prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.



We draw your attention to note 4 to the Standalone financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the Standalone financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter

For M Surendra & Associates

Chartered Accountants Firm Reg No. 0172805 dra & RN No.01728 CA Shaik Shavali P

CA Shaik Shavali I Partner M.No. 245517

UDIN: 24245517BKDASH3270

Place : Hyderabad Date: 29.03.2024

Plot No.59, Road No.12, TSIIC Tech Park, IDA Nacharam, Hyderabad-500 076

STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec, 2023

		1	Quarter Ende		Rs In lacs		
LNO.	PARTICULARS	Distriction and Discount of the		d	Nine month	Year Ended	
	TAKILOLAKS	31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
11	a) Revenue from operations b) Other Income	3.68	3.58	3.38	9.53	13.07	16.8
Ш	Total income (I+II)	3.68	3.58	3.38			
IV	Expenditure		0.00	3.35	9.53	13.07	16.8
	a) Cost of raw and packing materials consumed b) Purchase of Traded Products c) Changes of Inventories of Pinished Goods, Work in Progress	2,36	2.17	2.15	5.86	8.02	10.6
	and Stock in Trade d) Employee Benefits Expense e) Depreciation and amortization f) Finance Cost g) Other Expenses	2.67 0.54 0.07	3.01 0.54 0.04	5.15 0.70 0.07	9.78 1.62 0.15	13.86 2.10 0.22	20.0 2.8 0.2
1	Total expenses	1.48	1.08	10.58	8.68	22.47	40.3
V	Profit / (Loss) before exceptional items and Tax (III-IV)	7.11	6.84	18.65	26.08	46.67	74.0
VII VIII IX X	Exceptional items Profit / (Loss) before tax (V-VI) Tax expense Net Profit / (Loss) for the period (VII-VIII) Other Comprehensive Income, Total Other Comprehensive Income, net of Tax Fotal Comprehensive Income for the period	(3.43) (3.43) (3.43) (3.43)	(3.26) (3.26) (3.26) (3.26) (3.26)	(15.27) (15.27) (15.27) (15.27)	(16.56) (16.56) (16.56)	(33.60) (33.60) (33.60) (33.60)	(57.1) (57.1) (57.1)
an 1	aid-up Equity Share Capital (Face Value of Rs.10/- per share) farming Per Share for the Period	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
1	lasic Xiluted	(0.02) (0.02)	(0.01) (0.01)	(0.07) (0.07)	(0.07) (0.07)	(0.15) (0.15)	(0.25 (0.25

Notes

The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29,03:2024 25

2)


Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time. The Financial results and other financial information for the quarter ended 31st December, 2023 has been compiled by the management as per Ind AS, after 3)

excercising necessary due deligence , to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Reults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com The previous year comparitives are based on the audited financial statements which are approved by the board of directors but yet to be 41

adopted by the shareholders in the upcoming Anual general meating as the company has not complied with section 96 of the companies act 2013 recording conduction of Annal general meeting During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 at the beginning 5)

of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation

The company acquired 51.01% salves in X Ploro Chemistry capability centre Private Limited in the month of Dece 61





LIMITED REVIEW REPORT

To, The Board Members of Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited consolidated financial results of M/s Celestial Biolabs Limited for quarter ended 31 December ,2023", and year to date results for the period from 01 April 2023 to 31 December 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated Financial Results, prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.



We draw your attention to note 4 to the consolidated financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the consolidated financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

For M Surendra & Associates

& stb

RN No.0172805

Chartered Accountants Firm Reg No. 017280S

P. teic

CA Shaik Shavali P Partner M.No. 245517

UDIN: 24245517BKDASL1924

Place : Hyderabad Date: 27.03.2024

		-			and the second se	n lacs	
	Starte Statute Bare state State and	Quarter Ended			Nine month	Year Ended	
SL.NO.	PARTICULARS	31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
1 П	a) Revenue from operations b) Other Income	3.68	3.58	3.38	9.52	13.07	16.83
III	Total income (I+II)	3.68	3.58	3.38	9.52	13.07	16.85
IV	Expenditure		0100	0.00	1.04	10.07	10.07
372	a) Cost of raw and packing materials consumed b) Purchase of Traded Products c) Changes of Inventories of Finished Goods, Work in Progress	2.36	2.17	2.15	5.86	8.02	10.61
270	and Stock in Trade		-	14-1			
12204	d) Employee Benefits Expense	2.67	3.01	5.15	9.78	13.86	20.04
	e) Depreciation and amortization	0.54	0.54	0.70	1.62	2.10	2.83
	f) Finance Cost	0.07	0.04	0.07	0.15	0.22	0.8
	g) Other Expenses	1.84	1.08	10.58	9.18	22.47	40.69
	Total expenses	7.48	6.84	18.65	26.59	46.67	75.00
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(3.80)	(3.26)	(15.27)	(17.07)	(33.60)	(58.13
VI	Exceptional items		a contra	invite.	1.1	and a second	No.
VII	Profit / (Loss) before tax (V-VI)	(3.80)	(3.26)	(15.27)	(17.07)	(33.60)	(58.13
VIII	Tax expense	Nee-36	a sugar	1800.575	1000	and and	12/2/05
IX	Net Profit / (Loss) for the period (VII-VIII)	(3.80)	(3,26)	(15.27)	(17.07)	(33.60)	(58.13
101/2	- Pertaining to owners of the company	(3.62)	(3.18)	(15.27)	(16.53)	(33.60)	(57.6)
1	- Pertaining to non controlling interest	(0.18)	(0.08)		(0.53)		(0.46
X	Other Comprehensive Income,		103,5276.00		-		+
	Total Other Comprehensive Income, net of Tax	-	-				
XI	Total Comprehensive Income for the period	(3.80)	(3.26)	(15.27)	(17.07)	(33.60)	(58:13
	- Pertaining to owners of the company	(3.62)	(3.18)	(15.27)	(16.53)	(33.60)	(57.67
	- Pertaining to non controlling interest	(0.18)	(0.08)		(0.53)	•	(0.46
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period	100 Mar			and the second		- Alterative
	Basic	(0.02)	(0.01)	(0.07)	(0.07)	(0.15)	(0.26
100	Diluted	(0.02)	(0.01)	(0.07)	(0.07)	(0.15)	(0.26

CELESTIAL BIOLABS LIMITED Plot No.59, Road No.12, TSHC Tech Park, IDA Nacharam, Hyderabad-500 076 CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec, 2023

Notes

1) The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03.2024

 Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.

3) The Financial results and other financial information for the quarter ended 31st December,2023 has been compiled by the management as per Ind AS, after excercising necessary due deligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Reults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com

4) The previous year comparitives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Anual general meating as the company has not complied with section % of the companies act 2013 regarding conduction of Anual general meeting

5) During the Pinancial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation

6) The company acquired 51.61% sahres in X Ploro Chemistry capability centre Private Limited in the month of December 2022





LIMITED REVIEW REPORT

To, The Board Members of Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for quarter ended 30 September ,2023", and year to date results for the period from 01 April 2023 to 30 September 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Financial Results , prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed that it contains any material misstatement.



We draw your attention to note 4 to the standalone financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the standalone financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter

For M Surendra & Associates Chartered Accountants Firm Reg No. 017280S

FRM No.0172

P. Lece

CA Shaik Shavali P Partner M.No. 245517

UDIN: 24245517BKDASG3888

Place : Hyderabad Date: 29.03.2024

Г

Particulars	September 30, 2023	March 31, 2023
ASSETS		
Non- current assets		
(a) Property, Plant & Equipment	100	-
(b) Capital work - in - progress	6.90	7.9
(c) Financial Assets	1,281.58	1,281,5
(i) Investments in subsidiary company	0.00	
()	0.29	0.2
	1,288.77	1,289.8
Current Assets		
(a) Inventories	2.55	3.3
(b) Financial Assets		
(i) Trade receivables	366.87	370.75
(ii) Cash and cash equivalents	2.15	1.7
(iii) Other financial asset		
(c) Current Tax Assets (Net)		
(d) Other Current Assets	37.74	37.74
	409.31	413.58
TOTAL	1 (00.00)	1-242-T
EQUITY AND LIABILITIES	1,698.08	1,703.43
EQUITY		
(a) Equity share capital	0.050 /0	121223713
(b) Other Equity	2,258.63	2,258.63
철학은 다음 것 같은 것이 같은 것이 다른 다. 한다면 방법은 것이	-1,993.91	-1,980.78
Total equity	264.72	277.85
LIABILITIES		Serence of the series of the s
Non- current liabilities		
(a) Financial Liabilities		
(i). Borrowings	1000	
(ii). Trade Payables	886.98	885.81
(b) Deferred tax liabilities (Net)	1 - 2 1 - 1	
()		
Current liabilities	886.98	885.81
(a) Financial Liabilities		
	essione	
(i) Borrowings (ii) Trade payables	305.33	305.33
(a) Duce of micro ontermine and in 11		
(a) Dues of micro enterprise and small enterprises(b) Dues of creditors other than, micro enterprises		
and small enterprises	33.26	26.73
(iii) Other financial liabilities		
b) Other current liabilities	25.00	25.00
c) Provisins	182.78	182.71
ncome Tax liabilities(net)		
	E46.00	
	546.37	539.77
TOTAL	1,698.08	1,703.43
	and the second se	*// VU/3U

Managing Director

CELESTIAL BIOLABS LIMITED Plot No.59, Road No.12, TSIIC Tech Park, IDA Nacharam, Hyderabad-500 076 STANDALONE STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Sep, 2023

-		-			Rs In lacs	110	
	12/70212/2010-01/00	Quarter Ended			Six month p	Year Ended	
SL.NO.	PARTICULARS	30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
I n	a) Revenue from operations b) Other Income	3.58	2.20	4.18	5.84	9.69	16.8
щ	Total income (I+II)	3.58	2.26	4.18	5.84	9.69	16.8
IV	Expenditure a) Cost of raw and packing materials consumed b) Purchase of Traded Products c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	2.17	1.33	2.51	3.50	5.87	10.61
	d) Employee Benefits Expense	-				-	
	e) Depreciation and amortization	3.01	4.10	4.53	7.11	8.70	20.0
	f) Finance Cost	0.54	0.54	0.70	1.08	1.41	2.8
	g) Other Expenses	1.08	0.04 6.12	0.07	0.08	0.16	0.8
1	Total expenses	6.84	12.13	12.38	18.97	11.89 28.03	40.6
V	Profit / (Loss) before exceptional items and Tax (III-IV)	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.1)
VI	Exceptional items	A COLOR	Access of	(order)	(20120)	(1000)	100.4
	Profit / (Loss) before tax (V-VI)	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.13
	Tax expense	-		-		(10.00)	Printer.
	Net Profit / (Loss) for the period (VII-VIII)	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.1)
X	Other Comprehensive Income,	-		-		100	1000
XI	Total Other Comprehensive Income, net of Tax	URREN	1.5		ast free		
	Total Comprehensive Income for the period	(3.26)	(9.87)	(8.20)	(13.13)	(18.35)	(58.13
XII.	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
	Earning Per Share for the Period Basic Diluted	(0.01) (0.01)	(0.04) (0.04)	(0.04) (0.04)	(0.06) (0.06)	(0.08) (0.08)	(0.26 (0.2)

Notes

The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03,2024
 Financial Results for all the periods presented have been approved in periods and it's meeting held on 29.03,2024

Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
 The Financial results and other financial information for the question and at 2015 Science and 201

3) The Financial results and other financial information for the quarter ended 30th September,2023 has been compiled by the management as per Ind AS, after excercising necessary due deligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Retults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and In Company's website www.celestialbiolabs.com

The previous year comparitives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Anual general meating as the company has not complied with section 96 of the companies act 2013 regarding conduction of Anual general meeting

5) During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023 Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and appliying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation

6) The company acquired 51.01% sahres in X Ploro Chemistry capability centre Private Limited in the month of December 2022.

Managing Director

Standalone Cash Flow Statement For the Quarter ended 30th September, 2023

Particulars	Six months ended Sep 30, 2023	Six months ended Sep 30, 2022	year ended ended 31.03.2023
A.Cash Flow From Operating Activities			
Net Profit beforeTax & Appropriations	(13.13)	(18.35)	(57.19)
Depreciation & Amortisation of Intangible assets	1.08	1.41	2.83
Operating Profit Before Working Capital Charges	(12.05)	(16.94)	(54.36)
Adjustments for:			Star. 2
(Increase)/Decrease in Inventory	0.83	0.81	1.50
(Increase)/Decrease in Trade Receivables	3.87	8.49	12.52
(Increase)/Decrease in Other Curent Assets	-	(5.06)	
(Increase)/Decrease in Trade Payable	6.54	(2.24)	0.71
(Increase)/Decrease in Other financial liabilities			
(Increase)/Decrease in Other Current Liabilities	0.07	4.49	5.07
(Increase)/Decrease in Provisions			
Cash Generated from Operations	(0.73)	(10.44)	(34.56)
Net Cash generated from Operating Activities (A)	(0.73)	(10.44)	(34.56)
B.Cash Flow from Investing Activities:	1.3.5.0	2.02.3	
Purchases of fixd assets			(0.64)
Sale of Land and Building		(0.64)	
Investments in subsidiaries		-	(0.29)
Net Cash generated from/(Used) Investing Activities (B)		(0.64)	(0.93)
C.Cash Flow from Financial Activities			
Net Cash generated from/(used) Financial Activities (c)			
Increase/(Decrease) in Borrowings	1.17	12.23	37.07
Interest and Financial Charges Paid	28200	2211147633	100.000
	1.17	12.23	37.07
Net Increase/(Decrease) in Cash and Cash Equalants (A+B+C)	1 - I - Constant	1997 (19	05562722
	0.44	1.16	1.58
Cash and Cash equilants at the beginning of the year	1.71	0.13	0.13
Cash and Cash equilants (Closing Balance)	2.15	1.29	1.71

HYDERABAD Date: 29.03.2024 Managing Director



LIMITED REVIEW REPORT

To, The Board Members of Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited consolidated financial results of M/s Celestial Biolabs Limited for quarter ended 30 September ,2023", and year to date results for the period from 01 April 2023 to 30 September 2023 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated Financial Results, prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.



We draw your attention to note 4 to the consolidated financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.

We draw attention to Note 5 to the consolidated financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

For M Surendra & Associates

Chartered Accountants Firm Reg No. 0172805

CA Shaik Shavali P Partner M.No. 245517

UDIN: 24245517BKDASK7091

Place : Hyderabad Date: 29.03.2024

ſ

	September 30, 2023	March 31, 2023	
ASSETS			
Non- current assets			
(a) Property, Plant & Equipment	7150.88		
(b) Capital work - in - progress	6.90	7.9	
(c) Goodwill	1,281.58	1,281.50	
(c) Financial Assets	0.10	0.10	
(i) Investments in subsidiary company			
, mital	1,288.58	-	
Current Assets	1,200,30	1,289.66	
(a) Inventories	States and States and		
(b) Financial Assets	2.55	3.38	
(i) Trade receivables			
(ii) Cash and cash equivalents	366.87	370.76	
(iii) Other financial asset	2.61	2.33	
(c) Current Tax Assets (Net)			
(d) Other Current Assets	•		
	57.56	57.53	
	429.59	434.01	
TOTAL	1,718.17	1 000 (0	
EQUITY AND LIABILITIES	1,/10.1/	1,723.67	
EQUITY			
(a) Equity share capital	2,258.63	0.050.40	
(b) Other Equity	-1,994.48	2,258.63	
(c) Non controlling interest	-0.37	-1,981.26	
Total equity	263,78	-0.29 277.08	
LIABILITIES		4/7.00	
Non- current liabilities			
a) Financial Liabilities		2 8 8 A 1 A 1	
(i). Borrowings			
(ii). Trade Payables	898.91	897.74	
b) Deferred tax liabilities (Net)			
(and the difference (deel)	-		
Current liabilities	898.91	897.74	
a) Financial Liabilities			
(i) Borrowings		5. S 1 5 N	
(ii) Trade payables	305.33	305.33	
(a) Dues of micro anternales at a li		15.0009781	
(a) Dues of micro enterprise and small enterprises(b) Dues of creditors other than,micro enterprises		5.50 Th. 350	
and small enterprises	41.95	35.39	
(iii) Other financial liabilities			
) Other current liabilities	25.00	25.00	
) Provisins	183.21	183.12	
come Tax liabilities(net)		200	
	555.49	548.85	
TOTAL	1,718.17	1,723.67	

YE en. C Managing Director

100		Rs In lacs						
SL.NO		-	Quarter Ended	Six month p	Year Ended			
	PARTICULARS	30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023	30.09.2022 (Unaudited)	31.03.2023 (Audited)	
I II III	a) Revenue from operations b) Other Income	3,58	2.26	4.18	5.84	9.69	16.8	
iv	Total income (I+II)	3.58	2.26	4.18			-	
14	Expenditure		and a	4.10	5,84	9.69	16.8	
	a) Cost of raw and packing materials consumed b) Purchase of Traded Products c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	2.17	1.33	2.51	3,50	5.87	10.6	
	d) Employee Benefits Expense	1.1	18 1 2.4					
	e) Depreciation and amortization	3.01	4.10	4.53	7.11	8.70	20.0	
	f) Finance Cost	0.54	0.54	0.70	1.08	1.41	2.8	
	g) Other Expenses	0.04	0.05	0.07	0.09	0.16	0.8	
	Total expenses	1.24	6.12	4.56	7.53	11.89	40.65	
V	Profit / (Loss) before exceptional items and Tax (III, IV)	7.00	12.14	12.38	19.31	28.03	75.01	
	Exceptional items Profit / (Loss) before tax (V-VI) Tax expense	(3.42) (3.42)	(9.88) (9.88)	(8.20) - (8.20)	(13.47) (13.47)	(18.35) - (18.35)	(58.14	
	Net Profit / (Loss) for the period (VII-VIII) Pertaining to owners of the company Pertaining to non controlling interest	(3.42) (3.26)	(9.88) (9.88)	(8.20) (8.20)	(13.47) (13.38)	(18.35) (18.35)	(58.14	
$\mathbf{x} = \mathbf{y}$	Other Comprehensive Income.	(0.16)	(0.00)		(0.08)		(0.46	
	Total Other Comprehensive Income net of Tax	-						
AI -	Lotal Comprehensive Income for the period	(3.42)		1.600				
	Pertaining to owners of the company	(3.26)	(9.88)	(8.20)	(13.47)	(18.35)	(58.14	
1	Pertaining to non controlling interest	(0.16)	(9.88)	(8.20)	(13.38)	(18.35)	(57.67	
1	aid-up Equity Share Capital (Face Value of Rs 10/- ner	10.101	(0.00)		(0.08)	-	(0.46	
AH [8	narej	2,258.63	2,258.63					
III E	arning Per Share for the Period		4,430.03	2,258.63	2,258.63	2,258.63	2,258.63	
1.15	lasic Xluted	(0.01) (0.01)	(0.04) (0.04)	(0.04) (0.04)	(0.06)	(0.08)	(0.26)	

CELESTIAL BIOLABS LIMITED Plot No.59, Road No.12, TSIIC Tech Park, IDA Nacharam, Hyderabad-500 076 CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Sep, 2023

Notes

The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03.2024 11 2)

Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time. The Financial results and other financial information for the quarter ended 30th September, 2023 has been compiled by the management as per Ind 31

AS, after excercising necessary due deligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Reults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com

The previous year comparitives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Anual general meating as the company has not complied with section 96 of the companies act 2013 regarding. 4)

During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 lakhs at 5) the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023 Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and appliying for further renewal request for manufacture for sale of ayarveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going

6) The company acquired 51.01% salves in X Ploro Chemistry capability centre Private Limited in the month of December 2022



Consolidated Cash Flow Statement For the Quarter ended 30th September, 2023

Particulars	Six months ended Sep 30, 2023	Six months ended Sep 30, 2022	year ended ended31.03. 2023
A.Cash Flow From Operating Activities	00,2020	2022	2023
Net Profit beforeTax & Appropriations	(13.47)	(10.00)	(20.4/4)
Depreciation & Amortisation of Intangible assets	1.08	(18.35)	(58.14)
Operating Profit Before Working Capital Charges	(12.39)	1.41	2.83
Adjustments for:	(12.55)	(16.94)	(55.31)
(Increase)/Decrease in Inventory	0.83	0.91	
(Increase)/Decrease in Trade Receivables	4.04	0.81	1.50
(Increase)/Decrease in Other Curent Assets	(0.03)	8,49	12.52
	(0.05)	(5.06)	(2.17)
(Increase)/Decrease in Trade Payable	1.00		
(Increase)/Decrease in Other financial liabilities	6.56	(2.24)	2.43
(Increase)/Decrease in Other Current Liabilities	0.00		-
(Increase)/Decrease in Provisions	0.08	4.49	5.49
Cash Generated from Operations	10.000	12000.000	mething
Net Cash generated from Operating Activities (A)	(0.90)	(10.44)	(35.56)
o spanning manues (A)	(0.90)	(10.44)	(35.56)
B.Cash Flow from Investing Activities:			
Purchases of fixd assets	1/2/12634	1.00	
sale of Land and Building	0.00		(0.64)
Capital work in progress		(0.64)	-
Other intangible assets			-
ntangible assets under development		7.5.8	
mpact of subsidiary acquired in the business combination		12 12 12 12	
Net Cash generated from/(Used) Investing Activities (B)			(0.29)
Cash Flow from Financial Activities	0.00	(0.64)	(0.93)
ncrease/(Decrease) in Borrowings			
nterest and Financial Charges Paid	1.17	12.23	37.61
let Cash generated from/(used) Financial Activities (c)	and the second	- 1	2
let Increase/(Decrease) in Cash and Cash Equalants (A+B+C)	1.17	12.23	37.61
(A+B+C) (A+B+C)	the second		513/237/02/
ash and Cash equilants at the beginning of the year	0.28	1.16	1.12
ash and Cash equilants Acquired in the beginning of the year	2.33	0.13	0.13
ash and Cash equilants Acquired in the business combimation	I State State	and a second	Contes
ash and Cash equilants (Closing Balance)	-		1.07
cush equilarity (closing balance)	2.61	1.29	2.32

(8.83) Managing Director C



LIMITED REVIEW REPORT

To, The Board Members of Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited standalone financial results of M/s Celestial Biolabs Limited for quarter ended 30 June ,2023", ("The statement")

This statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

We draw your attention to note 4 to the standalone financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.



We draw attention to Note 5 to the standalone financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter.

For M Surendra & Associates Chartered Accountants

Firm Reg No. 017280S

P. their MI ERN No.0172

dra &

CA Shaik Shavali P Partner M.No. 245517

UDIN: 24245517BKDASF8507

Place : Hyderabad Date: 29.03.2024

CELESTIAL BIOLABS LIMITED
Plot No 82, Venkat Reddy Nagar, Narapally, Medchal, Malkajoiri Diet Hudershad, 500020
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

-		Rs In lacs Quarter Ended Year Ende						
SL.NO.	DADTION 100	-	Year Ended					
or no.	PARTICULARS	30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)			
1 H	a) Revenue from operations b) Other Income	2.26	3.79	5.51	16.8			
Ш	Total income (I+II)	2.26						
IV	Expenditure	2.20	3.79	5.51	16.8			
	a) Cost of raw and packing materials consumed b) Purchase of Traded Products	1.33	2.59	3.36	10.6			
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade				-			
	d) Employee Benefits Expense	4.10		Sec.				
-	e) Depreciation and amortization	0.54	6.18	4.18	20.0			
1	f) Finance Cost	0.04	0.73	0.70	2.8			
200	g) Other Expenses	2222000	0.01	0.08	0.23			
and a	Total expenses	6.12	17.87	7.33	40.34			
V	Profit / (Loss) before exceptional items and Tax (III-IV)	12.13	27.38	15.66	74.05			
VI	Exceptional items	(9.87)	(23.59)	(10.15)	(57.18			
VII	Profit / (Loss) before tax (V-VI)	10 000	and the second	and the second				
VIII	Tax expense	(9.87)	(23.59)	(10.15)	(57.18			
IX	Net Profit / (Loss) for the period (VII-VIII)		atras	Starly.				
X	Other Comprehensive Income,	(9.87)	(23.59)	(10.15)	(57.18			
	Total Other Comprehensive Income, net of Tax	1 (A)	*					
XI	Total Comprehensive Income for the period			÷				
XII [Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	(9.87)	(23.59)	(10.15)	(57.18			
XIII	Earning Per Share for the Period	2,258.63	2,258.63	2,258.63	2,258.63			
	Basic Diluted	(0.04)	(0.10)	(0.04)	(0.25			
201		(0.04)	(0.10)	(0.04)	(0.25			

Notes

The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03.2024 15

- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind 2) AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time. 3)
- The Financial results and other financial information for the quarter ended 30th June 2023 has been compiled by the management as per Ind AS, after excercising necessary due deligence , to ensure that the financial results provide true and fair view of the results in accordance with ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Reults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website
- The previous year comparitives are based on the audited financial statements which are approved by the board of directors but yet to be 4) adopted by the shareholders in the upcoming Anual general meating as the company has not complied with section 96 of the companies act 2013 regarding conduction of Anual general meeting
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 5) 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31,3,2023 Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubtruncertainty by engaging in settlement negotilations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation
- The company acquired 51 01% sahres in X Ploro Chemistry capability centre Private Limited in the m 6)

BIOLAR in Managing Direct



LIMITED REVIEW REPORT

To, The Board Members of Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited consolidated financial results of M/s Celestial Biolabs Limited for quarter ended 30 June ,2023", ("The statement")

This statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated Financial Results, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

We draw your attention to note 4 to the consolidated financial results, where the management had commented that the previous year comparatives are based on the financial statements approved by the board of directors but not yet adopted by the shareholders in the annual General Meeting (AGM) as the company has not complied with section 96 of the companies act 2013 regarding conduction of Annual general meeting. Our review is carried on based on these unadopted financial results carried forward to the current period.



We draw attention to Note 5 to consolidated financial results, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 5 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

For M Surendra & Associates Chartered Accountants

Firm Reg No. 017280S P. tere M

FRN No.01728

odra & A

CA Shaik Shavali P Partner M.No. 245517

UDIN: 24245517BKDASI4253

Place : Hyderabad Date: 29.03.2024

SL.NO				n lacs	
SLINO	PARTICULARS	Quarter Ende			Year Ende
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.202 (Audited)
1	a) Revenue from operations b) Other Income Total Income	2.26	3.79	5.51	16.
IV	Expenditure (I+II)	2.26	*		
18	cxpenditure	2.25	3.79	5.51	16.0
	a) Cost of raw and packing materials consumed b) Purchase of Traded Products c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	1.33	2.59	3.36	10.
	d) Employee Benefits Expense e) Depreciation and amortization f) Finance Cost g) Other Expenses	4.10 0.54 0.05	6.18 0.73 0.61	4.18	20.0 2.0
	Total expenses	6.12	18.22	0.08	0.8
V	Profit / (Loss) before exceptional items and Tax (III-IV)	12.14	28.33	15.66	40.6
	Profit / (Loss) before tax (V-VI) Tax expense Net Profit / (Loss) for the period (VII-VIII) Pertaining to owners of the company Pertaining to pon controlling integerst	(9.88) (9.88) (9.88) (9.88)	(24.54) (24.54) (24.54) (24.08)	(10.15) (10.15) (10.15) (10.15)	75.0 (58.1 (58.1) (58.1)
A 13	Other Comprehensive Income, otai Other Comprehensive Income, net of Tax	(0.00)	(0.46)	(10.15)	(57.67 (0.46
	Pertaining to owners of the company Pertaining to non-controlling	(9.88) (9.88)	(24.54) (24.08)	(10.15) (10.15)	(58.13 (57.67
II P	aid-up Equity Share Capital (Face Value of Rs.10/- per share)	(0.00)	(0.46)	1	(0.46
	arning Per Share for the Period	2,258.63	2,258.63	2,258.63	2,258.63
B	asic lluted	(0.04) (0.04)	(0.11) (0.11)	(0.04) (0.04)	(0.26) (0.26)

CELESTIAL BIOLABS LIMITED Plot No 82, Venkat Reddy Nagar, Narapally, Medchai, Malkajgiri Dist Hyderabad - 500039 CONSOLIDATION STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

Notes

1)

The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03 2024 2)


Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time. The Financial results and other financial information for the guarter ended 30th June 203 has been compiled by the management as per 3)

Ind AS, after excercising necessary due deligence , to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Reults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website 41

The previous year comparitives are based on the audited financial statements which are approved by the board of directors but yet to be adopted by the shareholders in the upcoming Anual general meating as the company has not complied with section 96 of the companies 5)

During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 lakhs at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023 Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation The company acquired 51 01% sahres in X Pioro Chemistry capability centre Private Limited in the month

6)



Г

	unts in Rs. Lakhs
March 31, 2023	March 31, 202
7.09	
Contraction of the second s	1 201 5
4,601.00	1,281.5
0.29	
1,289.84	1,291.7
3.38	4.0
- CIERO	4.8
370.76	383.2
1.71	0.1
	-
37.74	37.74
413.60	426.03
1,702.44	
1,/03.44	1,717.77
2 258 62	3.850.00
	2,258.63
(1)/00.77)	(1,923.59)
277.86	335.04
The second	
885.81	848.74
	040.74
885.91	
005.01	848.74
305.33	305.33
	303.35
26.73	26.01
	25.00
182.71	177.63
530 77	+ F00 11
002.07	533.98
1,703.44	1,717.76
COLORADO COL	and the second sec
	1,289.84 3.38 370.76 1.71 37.74 413.60 1,703.44 2,258.63 (1,980.77) 277.86 885.81 305.33 26.73 25.00 182.71 -

Standalone Cash Flow Statement For the year ended 31st March, 2023

Particulars	(Amounts in	n Rs. Lakhs
A.Cash Flow From Operating Activities	2022-23	2021-22
Net Profit before Tax & Appropriations		
Depreciation	(57.19)	(40.95
Provison for tax	2.83	3.02
Operating Profit Before Working Capital Charges		-
Adjustments for:	(54.36)	(37.93)
(Increase)/Decrease in Inventory		
(Increase)/Decrease in Trade Receivables	1.50	0.33
(Increase)/Decrease in Other Curent Assets	12.52	(5.26)
(Increase)/Decrease in Trade Payable		
(Increase)/Decrease in Other financial liability	0.71	(11.89)
(increase)/ Decrease in Other Current Linkikia		25.00
(Increase)/Decrease in Provisions	5.08	2.23
Cash Generated from Operations		-
Net Cash generated from Operating Activities (A)	(34.56)	(27.52)
	(34.56)	(27.52)
B.Cash Flow from Investing Activities:		14,50
urchase of fixed assets		2.1.124
nvestments In subsidiaries	(0.65)	(0.38)
Product development expenses	(0.29)	
Net Cash generated from/(Used) Investing Activities (B)		
reading from financial Activities	(0.93)	(0.38)
ncrease/(Decrease) in Borrowinge		
vet Cash generated from / (used) Financial A statistic	37.07	25.89
therease/(Decrease) in Cach and Cath	37.07	25.89
and the state of the second se	1.58	(2.01)
ash and Cash Equivalent (Closing Balance)	0.13	2.13
	1.71	0.13

As per our report of even date

For M Surendra & Associates Chartered Accountants Firm Reg 017280S

P. tere

CA Shaik Shavali P Partner MRN: 245517



For and on Behalf of the Board Celestial Biolabs Limited CIN: L72200TG1997RLC028

HYD.

Amif Kumar Singh Managing Director DIN: 01824426

Director DIN: 01448915

Place: Hyderabad Date: 29.03.2024

					Rs In lacs	and the second se
SL.NO.	PARTICULARS	Quarter Ended			Year to Date	
		31.03.2023 (audited)	31.12.2022 (Unaudited)	31.03.2022 (audited)	31.03.2023 (audited)	31.03.2022 (Audited)
1 11 11	a) Revenue from operations b) Other Income Total Income (I+II)	3.79	3.38	6.31	16.87	14.7
IV	Expenditure	3.79	3.38	6.31	16.87	14.7
	a) Cost of raw and packing materials consumed b) Purchase of Traded Products c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	2.59	2.15	3.90	10.61	8.9
	d) Employee Benefits Expense e) Depreciation and amortization f) Finance Cost g) Other Expenses	6 18 0 73 0.01	5 15 0.70 0.07	4.24 0.70	20.04 2.83 0.23	12 33 3 02 0 07
	Total expenses	17.87	10.58	24.99	40.35	31.36
V	Profit / (Loss) before exceptional items and Tax ///LIVA	27.39	18.64	33.82	74.06	55.70
	Exceptional items Profit / (Loss) before tax (V-VI) Tax expense Net Profit / (Loss) for the period (VII-VIII) Other Comprehensive Income, fotal Other Comprehensive Income, net of Tax Fotal Comprehensive Income for the period	(23.60) (23.60) (23.60) (23.60)	(15.26) (15.26) (15.26)	(27.51) (27.51) (27.51) (27.51)	(57.19) (57.19) (57.19)	(40.95 (40.95 (40.95
100 100	aid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	(57.19) 2,258.63	(40.95
E	lasic Muted	(0.10) (0.10)	(0.07) (0.07)	(0,12) (0.12)	(0.25) (0.25)	(0.18) (0.18)

CELESTIAL BIOLABS LIMITED Plot No.59, Road No.12, TSIIC Tech Park, IDA Nacharam, Hyderabad-500 076 STANDALONE STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March, 2023

Notes

The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29.03.2024 1)

2)

Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time. The Financial results and other financial information for the quarter ended 31st March 2023 has been compiled by the management as per Ind 3)

AS, after excercising necessary due deligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Reults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com 4)

During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 277.86 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and appliying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation The company acquired 51.01% sahres in X Ploro Chemistry capability centre Private Limited in the month of December 2022 5)

For M Surendra & Associates Ata & Chartered Accountants Firm Reg 017280S Patero RN No.017280 CA Shaik Shavali P Partner MRN: 245517 d And

For and on Behalf of the Board Celestial Biolabs Limited CIN: L72200TG1997PLC0

Amit Komar Singh Managing Director DIN: 01824426

0

Padma Singh Director DIN: 01448915

Place Hyderabad Date: 29 03 2024



INDEPENDENT AUDITOR'S REPORT

To, The Board Members of Celestial Biolabs Limited

Opinion

We have audited the accompanying Statement of standalone Financial Results of Celestial Biolabs Limited (the "Company"), for the three months and year 'ended March 31, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and

b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2023.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the standalone Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion



Material Uncertainty on Going Concern

We draw attention to note 4 of the Statement, which indicates that the Company has significant losses and its net worth has been significantly eroded, the Company has a net loss during the current year. These conditions, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. However, based upon the measures as set forth in the note 4, including necessary financial support from a significant promoter shareholder, the management and the Board of Directors of the Company have a reasonable expectation that the Company will be able to realise its assets and discharge all its contractual obligations and liabilities as they fall due in near future in the normal course of the business. Accordingly, management has prepared the financial statements on a going concern basis.

Our Opinion is not modified in respect of this matter.

Management's Responsibilities for the Financial Results

These annual financial results have been prepared on the basis of the annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual standalone financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process



Auditor's Responsibilities for the Audit of the Annual standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the annual standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the annual standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting
 estimates and related disclosures in the standalone financial results made by the Management
 and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual standalone financial results, including the disclosures, and whether the annual standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation
- Obtain sufficient appropriate audit evidence regarding the standalone Financial Results of the Company to express an opinion on the standalone Financial Results.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Emphasis of Matter

The Company has long-term borrowings with State bank of India and the bank sanctioned the One Time Settlement (which has expired on date) for Rs 305.22 lakhs. The Company is carrying the One Time Settlement amount as the closing balance and has not recognized interest expense.

For M Surendra & Associates

Chartered Accountants Firm Reg No. 0172805

CA Shaik Shavali P Partner M.No. 245517

UDIN: 24245517 BKDASC 6876

Place : Hyderabad Date: 29.03.2024

Г

CONSOLIDATED BALANCE SHEET	and all an and a	Amount in Lac	
Particulars	March 31, 2023	March 31, 202	
ASSETS			
Non- current assets			
(a) Property, Plant & Equipment	7.98	10.10	
(b) Capital work - in - progress	1,281.58	1,281.5	
(c) Goodwill	0.10		
	1,289.66	1,291.74	
	4,000,100	1,624.01	
Current Assets			
(a) Inventories	3.38	4.8	
(b) Financial Assets		1.00	
(i) Trade receivables	370.76	383.2	
(ii) Cash and cash equivalents	2.33	0.1	
(iii) Other financial asset			
(c) Current Tax Assets (Net)			
(d) Other Current Assets	57.53	37.74	
	434.01	426.03	
TOTAL	1,723.67	1,717.73	
EQUITY AND LIABILITIES			
EQUITY	and the second se	100855385	
(a) Equity share capital	2,258.63	2,258.6	
(b) Other Equity	(1,981.26)	(1,923.5)	
(c) Non controlling interest	-0.29		
Total equity	277.08	335.04	
LIABILITIES			
Non- current liabilities			
(a) Financial Liabilities	and a	87,500	
(i). Borrowings	897.74	848.74	
(ii). Trade Payables			
(b) Deferred tax liabilities (Net)			
	897.74	848.74	
Current liabilities			
(a) Financial Liabilities			
(i) Borrowings	305:33	305.33	
(ii) Trade payables		Dawwe	
(a) Dues of micro enterprise and small enterprises			
(b) Dues of creditors other than, micro enterprises	35.39	26.01	
and small enterprises		20.0.	
(iii) Other financial liabilities	25.00	25.00	
b) Other current liabilities	183.12	177.64	
c) Provisins	163.12	177.64	
Income Tax liabilities(net)			
	548.84	533.98	
TOTAL	1,723.67	1,717.77	
	-0.00		
As per our report of even date 5	-0.00		
For M Surendra & Associates Chartered Accountants Firm Reg No 0172805	ted		

CA Shaik Shavali P Partner MRN: 245517

Place: Hyderabad Date: 29.03.2024

Minit Kumar Singh Managing Director DIN: 01824426

ha Singh Director DIN: 01448915

					Rs In lacs	
SL.NO.	PARTICULARS 31.03.2023	uarter Ended		Year to Date		
		12101232550(23)	31.12.2022 (Unaudited)	31.03.2022 (Unaudited)	31.03.2023 (Audited)	31.03.2022 (Audited)
11 111	a) Revenue from operations b) Other Income	3.79	3.38	6.31	16.87	14.75
	Total Income (I+II)	3.79	3.38	6.31	16.87	14.75
	Expenditure a) Cost of raw and packing materials consumed	2.59	2.15	3.90	10.61	8.93

6.18

0.73

0.61

18.22

28.33

(24.54)

(24.54)

(24.54)

(24.08)

(0.46)

(24.54)

(0.11)

(0.11)

2.258.63

5.15

0.70

0 07

10.58

18.64

(15.26)

(15.26)

(15.26)

(15.26)

(0.07)

(0.07)

2,258.63

4.24

0.70

24.99

33.82

(27.51)

(27.51)

(27.51)

(27.51)

(0.12)

(0.12)

2,258.63

20.04

2.83

0.83

40.69

75.00

(58.13)

(58.13)

(58.13)

(57.67)

(0.46)

(58.13)

(0.26)

(0.26)

2,258.63

12.32

3.02

0.07

31.36

55.69

(40.94)

(40.94)

(40.94)

(40.94)

(0.18)

(0.18)

2,258.63

CELESTIAL BIOLABS LIMITED Plot No.59, Road No.12, TSIIC Tech Park, IDA Nacharam, Hyderabad-500 076 ONSOLIDATION STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March, 2023

Notes

V

VI

VII

VIII

1X

X

XI

XII

XIII

Basic

Diluted

The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 29,03,2024

2) Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules , 2015 as amended from time to time

3) The Financial results and other financial information for the quarter ended 31st March 2023 has been compiled by the management as per ind AS, after excercising necessary due deligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only sbuject to review of statutory auditors. Reults are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com

4) During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 277.08 lakhs for year ended 31.3.2023. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation

5) The company acquired 51.01% sahres in X Ploro Chemistry capability centre Private Limited in the month of December 2022

For M Surendra & Associates Chartered Accountants Firm Reg No 017280S

b) Purchase of Traded Products

d) Employee Benefits Expense

Profit / (Loss) before tax (V-VI)

Other Comprehensive Income,

Earning Per Share for the Period

Net Profit / (Loss) for the period (VII-VIII)

Pertaining to owners of the company

Pertaining to non controlling interest

Total Other Comprehensive Income, net of Tax

Total Comprehensive Income for the period

e) Depreciation and amortization

and Stock in Trade

f) Finance Cost

Total expenses

Exceptional items

Tax expense

g) Other Expenses

c) Changes of Inventories of Finished Goods, Work in Progress

Paid-up Equity Share Capital (Face Value of Rs.10/- per share)

Profit / (Loss) before exceptional items and Tax (III-IV)

P. J-OCO CA Shalk Shavali P

Partner MRN: 245517

Place: Hyderabad Date: 29 03 2024

& stb. RN No.017280

For and on Behalf of the Bo Celestial Biolabs Limite OLA 028 CIN: L72200TG1997 7 in 3 AR Kumar Singh 33 6 Managing Director Э * DIN: 01824426 DIN 01448915

Consolidated Cash Flow Statement For the year ended 31st March, 2023 Particulars		nt In Lac
	2022-23	2021-22
A.Cash Flow From Operating Activities	A Contraction	TO VOLUMAN
Net Profit beforeTax & Appropriations	(58.14)	(40.95
Depreciation	2.83	3.02
Provison for tax		
Operating Profit Before Working Capital Charges	(55.31)	(37.93
Adjustments for:		
(Increase)/Decrease in Inventory	1.50	0.33
(Increase)/Decrease in Trade Receivables	12.52	(5.26
(Increase)/Decrease in Other Curent Assets	(2.17)	
(Increase)/Decrease in Trade Payable	2.43	(11.89
(Increase)/Decrease in Other financial liabilities	-	25.00
(Increase)/Decrease in Other Current Liabilities	5.49	2.23
(Increase)/Decrease in Provisions		
Cash Generated from Operations	(35.56)	(27.52
Net Cash generated from Operating Activities (A)	(35,56)	(27.52
B.Cash Flow from Investing Activities:		
Purchase of fixed assets	(0.64)	(0.38
Capital work in progress		
Other intangible assets		
Intangible assets under development	HURSEN R	-
Impact of subsidiary acquired in the business combination	(0.29)	5
Interest earned	,	
Product development expenses		
Net Cash generated from/(Used) Investing Activities (B)	(0.92)	(0.38
C.Cash Flow from Financial Activities		An other
Net Cash generated from/(used) Financial Activities (c)		
Increase/(Decrease) in Borrowings	37.61	25.89
	37.61	25.89
Net Increase/(Decrease) in Cash and Cash Equalants (A+B+C)	1.13	(2.01)
Cash and Cash equilants at the beginning of the year	0.13	2.13
Cash and cash equivalents acquired in the business combination	1.07	ener!
Cash and Cash equilants (Closing Balance)	2.32	0.13

As per our report of even date

For M Surendra & Associates Chartered Accountants Firm Reg No 017280S

CA Shaik Shavali P Partner MRN: 245517 ACCOMPTING ACCOUNTS

Place: Hyderabad Date: 29.03.2024

For and on Behalf of the Board Celestial Biolabs Limited CIN: L72200T01997PLC028374 HYD Wagma Singh 30 * Amit Kumar Sing

Managing Director DIN: 01824426

Director DIN: 01448915



INDEPENDENT AUDITOR'S REPORT

To, The Board Members of Celestial Biolabs Limited

Opinion

We have audited the accompanying Statement of consolidated Financial Results of Celestial Biolabs Limited (the "Company"), for the three months and year 'ended March 31, 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and

b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Group for the three months and year ended March 31, 2023.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion

Material Uncertainty on Going Concern

We draw attention to note 4 of the Statement, which indicates that the Group has significant losses and its net worth has been significantly eroded, the Group has a net loss during the current year. These conditions, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. However, based upon the measures as set forth in the note 4, including necessary financial support from a significant promoter shareholder, the management and the Board of Directors of the Company have a reasonable expectation that the Company will be able to realise its assets and discharge all its contractual obligations and liabilities as they fall due in near future in the normal course of the business. Accordingly, management has prepared the consolidated financial statements on a going concern basis.

Our Opinion is not modified in respect of this matter.

Management's Responsibilities for the consolidated Financial Results

These consolidated annual financial results have been prepared on the basis of the annual consolidated financial statements.

The Group's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the net profit and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annualconsolidation financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual consolidation financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of consolidated financial statements on whether the company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting
 estimates and related disclosures in the consolidated financial results made by the Management
 and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidate annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation
- Obtain sufficient appropriate audit evidence regarding the consolidated Financial Results of the Company to express an opinion on the consolidated Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Emphasis of Matter

The Company has long-term borrowings with State bank of India and the bank sanctioned the One Time Settlement (which has expired on date) for Rs 305.22 lakhs. The Group is carrying the One Time Settlement amount as the closing balance and has not recognized interest expense.

> For M Surendra & Associates Chartered Accountants Firm Reg No. 0172805

CA Shaik Shavali P Partner M.No. 245517

UDIN: 24245517BKDASE1599

Place : Hyderabad Date: 29.03.2024



CIN- L72200TG1997PLC028374

Date: 29.03.2024

To,

Department of Corporate Services	National Stock Exchange of India Ltd
BSE Limited	Exchange Plaza
Floor 25, PJ Towers	Bandra Kurla Complex
Dalal Street,	Bandra (E)
Mumbai – 400 001	Mumbai 400 051

Dear Sir,

Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015.

We hereby declare under the provisions of SEBI (LODR) Regulations, 2015 that the Auditors of the Company M/s M Surendra and Associates, Chartered Accountants (Firm Regn No. 017280S) have issued Independent Auditor's Report for the financial year 2022-2023 with unmodified opinion on Standalone and Consolidated Financial Statements as prepared under the provisions of Companies Act, 2013.

Kindly ackowledge the receipt of the same.

Thanking you

Yours truly For Celestial Biolabs Limited

AMIT Digit KUMAR Digit SINGH Digit AMIT Date 18:22

Digitally signed by AMIT KUMAR SINGH Date: 2024.03.29 18:22:20 +05'30'

Amit Kumar Singh Managing Director DIN: 01824426